e-Therapeutics plc e-therapeutics to present at Shares Evening
16 February 2021 - 6:00PM
RNS Non-Regulatory
TIDMETX
e-Therapeutics plc
16 February 2021
e-therapeutics PLC
e-therapeutics to present at Shares Investor Evening
Oxford, UK, 16 February 2021 - e-therapeutics plc (AIM: ETX.L,
"e-therapeutics" or "the Company") will be presenting at the Shares
Investor Evening - Webinar sponsored by AJ Bell on Wednesday 17(th)
February 2021. The webinar will start at 18:00 BST and investors
can register to attend here :
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-170221
Ali Mortazavi, Chairman & CEO of e-therapeutics, will be
presenting an overview of the Company and will be available to take
questions during the event.
-Ends-
For further information, please contact:
e-therapeutics plc
Ali Mortazavi, Chairman & CEO Tel: +44 (0)1993 883 125
www.etherapeutics.co.uk
Numis Securities Limited
Freddie Barnfield/Duncan Monteith (Nominated Adviser)
James Black (Corporate Broking)
Tel: +44 (0) 207 260 1000
www.numis.com
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a
powerful computer-based approach to drug discovery, founded on its
industry-leading expertise in network biology to fully capture
disease complexity. The Company combines network science, machine
learning, artificial intelligence, statistics and big data with
expertise in drug discovery and development to transform the search
for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that
enables the rapid screening of millions of compounds and the
identification of small sub-sets that are enriched for highly
active hits. Its proprietary platform also has novel applications
in functional genomics, being able to analyse complex genetic
datasets, provide a deep understanding of pathological mechanisms
and distil actionable insights for the discovery of novel drugs,
biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic
drug discovery platform both in house and with partners, including
Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical
company.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUVOBRAWUUAAR
(END) Dow Jones Newswires
February 16, 2021 02:00 ET (07:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024